148 related articles for article (PubMed ID: 37148323)
1. Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.
Jang S; Strickland B; Finis L; Kooijman JJ; Melis JJTM; Zaman GJR; Van Tornout J
Cancer Chemother Pharmacol; 2023 Jun; 91(6):491-499. PubMed ID: 37148323
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Activity of Rivoceranib Against Canine Mammary Gland Tumor Cell Lines.
Lee JH; Li Q; An JH; Chae HK; Choi JW; Kim BJ; Song WJ; Youn HY
Anticancer Res; 2019 Oct; 39(10):5483-5494. PubMed ID: 31570442
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models.
Li Q; Kim YS; An JH; Kwon JA; Han SH; Song WJ; Youn HY
BMC Vet Res; 2021 Oct; 17(1):338. PubMed ID: 34702279
[TBL] [Abstract][Full Text] [Related]
5. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
6. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.
Kankanala J; Latham AM; Johnson AP; Homer-Vanniasinkam S; Fishwick CW; Ponnambalam S
Br J Pharmacol; 2012 May; 166(2):737-48. PubMed ID: 22141913
[TBL] [Abstract][Full Text] [Related]
7. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
[TBL] [Abstract][Full Text] [Related]
9. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
[TBL] [Abstract][Full Text] [Related]
10. A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.
Bold G; Schnell C; Furet P; McSheehy P; Brüggen J; Mestan J; Manley PW; Drückes P; Burglin M; Dürler U; Loretan J; Reuter R; Wartmann M; Theuer A; Bauer-Probst B; Martiny-Baron G; Allegrini P; Goepfert A; Wood J; Littlewood-Evans A
J Med Chem; 2016 Jan; 59(1):132-46. PubMed ID: 26629594
[TBL] [Abstract][Full Text] [Related]
11. Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling.
Lu J; Zhang K; Nam S; Anderson RA; Jove R; Wen W
Carcinogenesis; 2010 Mar; 31(3):481-8. PubMed ID: 19969552
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent.
Jiang Z; Wang L; Liu X; Chen C; Wang B; Wang W; Hu C; Yu K; Qi Z; Liu Q; Wang A; Liu J; Hong G; Wang W; Liu Q
Acta Pharm Sin B; 2020 Mar; 10(3):488-497. PubMed ID: 32140394
[TBL] [Abstract][Full Text] [Related]
13. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2.
Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA
Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755
[TBL] [Abstract][Full Text] [Related]
15. VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability.
Gorbunova EE; Gavrilovskaya IN; Pepini T; Mackow ER
J Virol; 2011 Mar; 85(5):2296-303. PubMed ID: 21177802
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Hanna GJ; Ahn MJ; Muzaffar J; Keam B; Bowles DW; Wong DJ; Ho AL; Kim SB; Worden F; Yun T; Meng X; Van Tornout JM; Conlan MG; Kang H
Clin Cancer Res; 2023 Nov; 29(22):4555-4563. PubMed ID: 37643133
[TBL] [Abstract][Full Text] [Related]
17. In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.
Latham AM; Kankanala J; Fearnley GW; Gage MC; Kearney MT; Homer-Vanniasinkam S; Wheatcroft SB; Fishwick CW; Ponnambalam S
PLoS One; 2014; 9(11):e110997. PubMed ID: 25393739
[TBL] [Abstract][Full Text] [Related]
18. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
19. Discovery of highly potent and selective VEGFR2 kinase inhibitors for the treatment of rheumatoid arthritis.
Chen Q; Chen Z; Li F; Zha H; He W; Jiang F; Wei J; Xu J; Li R; Cai L; Liu X
Eur J Med Chem; 2023 Sep; 257():115456. PubMed ID: 37216810
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis.
El-Miligy MM; Abd El Razik HA; Abu-Serie MM
Future Med Chem; 2017 Oct; 9(15):1709-1729. PubMed ID: 28925739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
